Wedbush Reaffirms “Outperform” Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a note issued to investors on Thursday, June 26th, MarketBeat.com reports.

A number of other analysts also recently issued reports on VOR. JMP Securities reaffirmed a “market perform” rating and issued a $6.00 price objective on shares of Vor Biopharma in a research note on Friday, May 9th. Jones Trading lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Citizens Jmp downgraded shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 9th. HC Wainwright reiterated a “neutral” rating on shares of Vor Biopharma in a research report on Friday, May 9th. Finally, Baird R W cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $5.63.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock traded up $0.44 during trading on Thursday, reaching $1.89. 24,491,873 shares of the stock traded hands, compared to its average volume of 4,216,590. Vor Biopharma has a 52-week low of $0.13 and a 52-week high of $2.04. The business has a fifty day simple moving average of $0.41 and a two-hundred day simple moving average of $0.84. The company has a market capitalization of $235.55 million, a price-to-earnings ratio of -1.14 and a beta of 2.04.

Institutional Investors Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Vor Biopharma during the 4th quarter worth about $33,000. Money Concepts Capital Corp lifted its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after purchasing an additional 26,535 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Vor Biopharma during the fourth quarter valued at approximately $60,000. Goldman Sachs Group Inc. boosted its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Vor Biopharma during the fourth quarter valued at approximately $80,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.